Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancer
Patrick Micke(Uppsala University Hospital), Özlem Türeci(Johannes Gutenberg University Mainz)
Cited by 132
Related Papers
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
|Nature|2021|828